Skip to content

Study compares sevoflurane and propofol when used individually as inducing agents for insertion of supraglottic airway device.

A COMPARISON OF PROPOFOL VERSUS SEVOFLURANE FOR SUPRAGLOTTIC AIRWAY DEVICE INSERTION

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/06/043227
Enrollment
140
Registered
2022-06-13
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Control Intervention1: Propofol: route - intravenous, Dose 2-3mg/kg, Duration of induction - 2-5mins Control Intervention2: Sevoflurane: route - inhalational, Dose 6-8 MAC, Duration of induction 5-10m

Sponsors

MAJ DR AKSHAY CHANDRASHEKAR GUNDALLI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A. 140 ASA Grade I or II patients, between 20 and 70 years of age, undergoing general anaesthesia for short surgery ( B. Willing for valid consent.

Exclusion criteria

Exclusion criteria: 1. If they were predicted to have a difficult airway (Mallampatti Grade III or IV), ASA 3 and more, had a history of GI reflux, were receiving anti-epileptic medication, had a history of cardio-vascular, renal, hypertensive disease or known allergy to any anaesthetic. 2. Patients who are unable to open their mouth, supraglottic blockage.

Design outcomes

Primary

MeasureTime frame
Comparison of sevoflurane and propofol in ease of insertion of supraglottic airway device (Thermoplastic Elastomer) insertion in patients undergoing short surgery.Timepoint: 24 28 weeks

Secondary

MeasureTime frame
Loss of eye las reflex, Hemodynamic parameters, Jaw opening, ease of insertion, coughing, gagging, laryngeal spasmTimepoint: 24-28weeks

Countries

India

Contacts

Public ContactMASTI NAGENDRARAO VIJAI

Organization - Indian Armed Forces

vijaymn7@yahoo.co.in9910230411

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026